SCHEDULE: Soleus Capital Discloses 7.6% Stake in Context Therapeutics
Schedule 13G (Beneficial Ownership Report)
Soleus Capital Master Fund and affiliated entities have reported a 7.6% beneficial ownership stake in Context Therapeutics Inc.
Summary
- Soleus Capital Master Fund, L.P. and its affiliates have filed a Schedule 13G indicating beneficial ownership of 6,963,141 shares of Context Therapeutics Inc. common stock.
- This holding represents 7.6% of the company's total outstanding common stock, based on 91,879,177 shares outstanding as of May 4, 2026.
- The reporting persons include Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, and Guy Levy.
- The filing confirms that these shares are held for investment purposes and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral-to-positive development, as it reflects institutional interest in the company's equity without indicating any immediate strategic shift or management conflict.
Positives
- Institutional investor confidence is demonstrated by the accumulation of a significant 7.6% equity position.
Negatives
- None identified in this regulatory disclosure.
Risks
- The investment is subject to market volatility and the general risks associated with the biotechnology sector.
Future Outlook
The reporting persons state that the securities were not acquired for the purpose of changing or influencing the control of the issuer.
Industry Context
StockSavvy.ai notes that institutional filings of this nature are standard in the biotech sector, often signaling long-term investment interest from specialized healthcare funds like Soleus Capital.
Comparison to Industry Standards
- The 7.6% stake is consistent with typical institutional ownership thresholds for small-cap biotechnology companies.
- The filing follows standard SEC Schedule 13G requirements for passive investors.
Stakeholder Impact
- Shareholders may view the entry of a significant institutional investor as a validation of the company's long-term prospects.
Next Steps
- The reporting persons will continue to monitor their investment in Context Therapeutics Inc.
Key Dates
| Date | Description |
|---|---|
| 03/31/2026 | Date of event which requires filing of this statement. |
| 05/04/2026 | Date used for total shares outstanding calculation. |
| 05/06/2026 | Date of the Issuer's Quarterly Report on Form 10-Q. |
| 05/08/2026 | Date of the Schedule 13G filing. |
Keywords
Context Therapeutics, Soleus Capital, Schedule 13G, Institutional Ownership, Biotech Investment, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.